Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Lucas

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry|September 6, 2002
Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinaseGabriela Chiosis, Brian Lucas, Alexander Shtil, et al.
JAMA Pediatrics|January 29, 2019
Association of Diagnostic Criteria With Urinary Tract Infection Prevalence in Bronchiolitis: A Systematic Review and Meta-analysisCorrie E McDaniel, Shawn Ralston, Brian Lucas, et al.
Current Cancer Drug Targets|October 8, 2003
Development of purine-scaffold small molecule inhibitors of Hsp90Gabriela Chiosis, Brian Lucas, Henri Huezo, et al.
Inorganic Chemistry|June 18, 1997
Pressure Dependence Investigation of the Low-Temperature Structure of TlAu(CN)(2) by High-Resolution Neutron Powder Diffraction and Optical StudiesPeter Fischer, Joël Mesot, Brian Lucas, et al.
Chemistry & Biology|June 26, 2004
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90Maria Vilenchik, David Solit, Andrea Basso, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2020
Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activatorsBin Ma, Brian Lucas, Andrew Capacci, et al.
ACS Chemical Neuroscience|February 22, 2023
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective InhibitorsBrenda Amaral, Andrew Capacci, Trip Anderson, et al.
Science Signaling|August 2, 2018
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signalingKate L Henry, Debra Kellner, Bekim Bajrami, et al.
Journal of Medicinal Chemistry|December 4, 2014
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune diseaseTimothy D Cushing, Xiaolin Hao, Youngsook Shin, et al.
Cancer Discovery|September 27, 2018
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSean Caenepeel, Sean P Brown, Brian Belmontes, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry|September 6, 2002
Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinaseGabriela Chiosis, Brian Lucas, Alexander Shtil, et al.
JAMA Pediatrics|January 29, 2019
Association of Diagnostic Criteria With Urinary Tract Infection Prevalence in Bronchiolitis: A Systematic Review and Meta-analysisCorrie E McDaniel, Shawn Ralston, Brian Lucas, et al.
Current Cancer Drug Targets|October 8, 2003
Development of purine-scaffold small molecule inhibitors of Hsp90Gabriela Chiosis, Brian Lucas, Henri Huezo, et al.
Inorganic Chemistry|June 18, 1997
Pressure Dependence Investigation of the Low-Temperature Structure of TlAu(CN)(2) by High-Resolution Neutron Powder Diffraction and Optical StudiesPeter Fischer, Joël Mesot, Brian Lucas, et al.
Chemistry & Biology|June 26, 2004
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90Maria Vilenchik, David Solit, Andrea Basso, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2020
Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activatorsBin Ma, Brian Lucas, Andrew Capacci, et al.
ACS Chemical Neuroscience|February 22, 2023
Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective InhibitorsBrenda Amaral, Andrew Capacci, Trip Anderson, et al.
Science Signaling|August 2, 2018
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signalingKate L Henry, Debra Kellner, Bekim Bajrami, et al.
Journal of Medicinal Chemistry|December 4, 2014
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune diseaseTimothy D Cushing, Xiaolin Hao, Youngsook Shin, et al.
Cancer Discovery|September 27, 2018
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSean Caenepeel, Sean P Brown, Brian Belmontes, et al.
Pageof 3